Hypoxia is a condition characterized by
inability of the tissues to receive an adequate oxygen supply. This condition
is categorized into four types; hypoxic, stagnant, anaemic, fulminating, and
histotoxic hypoxia. Hypoxic hypoxia is defined as the lack of oxygen in the
arterial blood while in stagnant hypoxia, the rate at which blood circulates in
the body is decreased.
Access
Detailed Report Summary:
Fulminating
hypoxia is an induced type of hypoxia through inhalation of undiluted inert
gases. The lack of the haemoglobin causes less intake of oxygen in the blood,
resulting in the development of anaemic hypoxia. Histotoxic hypoxia occurs due
to cyanide poisoning, in which the tissues are unable to accept oxygen from
capillaries.
Request
to Get the Sample Pages at:
Global Blood
Therapeutics Inc. is in the process of developing GBT440 as an abnormal
haemoglobin modulator for the treatment of hypoxia. NuvOx Pharma LLC is in the
process of developing NVX-108 for the treatment of hypoxia. Akebia Therapeutics
Inc. is also involved in the pipeline for Hypoxia.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.